Literature DB >> 18336966

Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine.

Audrey Ferrier-Rembert1, Robert Drillien, Jean-Nicolas Tournier, Daniel Garin, Jean-Marc Crance.   

Abstract

This study assessed three non-replicating smallpox vaccine candidates (modified vaccinia Ankara (MVA), NYVAC and HR) for their immunogenicity and ability to protect mice against an intranasal cowpox virus challenge and compared them with the traditional replicating vaccine. A single immunisation with the non-replicating vaccines induced a complete protection from death at short-term, but was not fully protective when mice were challenged 150 days post-vaccination with protection correlated with the specific neutralizing antibodies and CD4(+) T-cells responses. Prime-boost vaccination enabled effective long-term protection from death for mice vaccinated with MVA, but protection from disease and CD4(+) T-cell level were lower than the ones induced by the traditional vaccine over the long-term period. Further investigations are necessary with MVA to determine the optimal conditions of immunisation to induce at long-term immunogenicity and protection observed with the 1st generation smallpox vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18336966     DOI: 10.1016/j.vaccine.2007.12.059

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice.

Authors:  Shahram Salek-Ardakani; Rachel Flynn; Ramon Arens; Hideo Yagita; Geoffrey L Smith; Jannie Borst; Stephen P Schoenberger; Michael Croft
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

3.  The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys.

Authors:  Jeffrey E Teigler; Sanjay Phogat; Genoveffa Franchini; Vanessa M Hirsch; Nelson L Michael; Dan H Barouch
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

Review 4.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

5.  Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.

Authors:  Julie Dimier; Audrey Ferrier-Rembert; Karine Pradeau-Aubreton; Matthias Hebben; Danièle Spehner; Anne-Laure Favier; Danielle Gratier; Daniel Garin; Jean-Marc Crance; Robert Drillien
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

6.  Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.

Authors:  Kristina E Rehm; Rachel L Roper
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

Review 7.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 8.  Smallpox vaccines for biodefense.

Authors:  Richard B Kennedy; Inna Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

9.  Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.

Authors:  José Luis Nájera; Carmen Elena Gómez; Juan García-Arriaza; Carlos Oscar Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

10.  Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax.

Authors:  Claire M Midgley; Mike M Putz; Jonathan N Weber; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2008-12       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.